Skip to main content

Table 4 Circulating calcium levels in control subjects and breast cancer cases expressing inactivating CaSR mutants stratified by race

From: Association of calcium sensing receptor polymorphisms at rs1801725 with circulating calcium in breast cancer patients

Control subjects

Breast cancer cases

SNP

Race

Genotype

n

Calcium (mg/dl)

p-valuea

n

Calcium (mg/dl)

p-valueb

rs1801725

Whites

G/G

203

8.96 ± 0.55

 

101

9.24 ± 0.39

 

G/T

63

9.16 ± 0.51

0.002

36

9.40 ± 0.43

0.034

Blacks

G/G

101

9.26 ± 0.48

 

53

9.30 ± 0.39

 

G/T

11

9.25 ± 0.39

0.83

5

9.26 ± 0.42

0.82

rs1801726

Whites

C/C

253

9.02 ± 0.56

 

132

9.29 ± 0.41

 

C/G

18

9.06 ± 0.51

0.69

9

9.29 ± 0.36

0.95

Blacks

C/C

75

9.31 ± 0.48

 

46

9.29 ± 0.40

 

C/G

32

9.21 ± 0.36

0.21

10

9.33 ± 0.39

0.95

  1. Difference in the mean circulating calcium between subjects expressing the wild type and the mutant receptor in control (a) or breast cancer cases (b). The p-values were calculated using the Wilcoxon rank sum test from the median with interquartile ranges for each group